Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; 2 MRC London Institute of Medical Sciences, Hammer- smith Hospital, London, UK; 3 Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK; 4 South London and Maud- sley Foundation NHS Trust, Maudsley Hospital, London, UK; 5 St. George's, University of London, London, UK
Список исп. литературыСкрыть список 1. Fusar-Poli P, McGorry PD, Kane JM. Improving outcomes of first-episode psychosis: an overview. World Psychiatry 2017;16:251-65. 2. McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia – An overview. JAMA Psychiatry 2020;77:201-10. 3. Johnstone EC, Crow TJ, Johnson AL et al. The Northwick Park Study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission. Br J Psychiatry 1986;148:115-20. 4. Norman RM, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol Med 2001;31:381-400. 5. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991;17:325-51. 6. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry 1998;172(Suppl. 33):53-9. 7. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry 1999;46:899-907. 8. Killackey E, Yung AR. Effectiveness of early intervention in psychosis. Curr Opin Psychiatry 2007;20:121-5. 9. McGorry PD. Early intervention in psychosis: obvious, effective, overdue. J Nerv Ment Dis 2015;203:310-8. 10. Csillag C, Nordentoft M, Mizuno M et al. Early intervention in psychosis: from clinical intervention to health system implementation. Early Interv Psychiatry 2018;12:757-64. 11. McDaid D, Park A-L, Iemmi V et al. Growth in the use of early intervention for psychosis services: an opportunity to promote recovery amid concerns on health care sustainability. London: Personal Social Services Research Unit, 2016. 12. Omer S, Behan C, Waddington JL et al. Early intervention in psychosis: service models worldwide and the Irish experience. Irish J Psychol Med 2010;27:210-4. 13. Cheng C, Dewa CS, Langill G et al. Rural and remote early psychosis intervention services: the Gordian knot of early intervention. Early Interv Psychiatry 2014;8:396-405. 14. Verma S, Poon LY, Lee H et al. Evolution of early psychosis intervention services in Singapore. East Asian Arch Psychiatry 2012;22:114-7. 15. Mascayano F, Nossel I, Bello I et al. Understanding the implementation of coordinated specialty care for early psychosis in New York state: a guide using the RE-AIM framework. Early Interv Psychiatry 2019;13:715-9. 16. Marshall M, Lewis S, Lockwood A et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005;62:975-83. 17. Perkins DO, Gu H, Boteva K et al. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005;162:1785-804. 18. Boonstra N, Klaassen R, Sytema S et al. Duration of untreated psychosis and negative symptoms – a systematic review and meta-analysis of individual patient data. Schizophr Res 2012;142:12-9. 19. Penttila M, Jaaskelainen E, Hirvonen N et al. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2014;205:88-94. 20. Santesteban-Echarri O, Paino M, Rice S et al. Predictors of functional recovery in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies. Clin Psychol Rev 2017;58:59-75. 21. Allott K, Fraguas D, Bartholomeusz CF et al. Duration of untreated psychosis and neurocognitive functioning in first-episode psychosis: a systematic review and meta-analysis. Psychol Med 2018;48:1592-607. 22. Bora E, Yalincetin B, Akdede BB et al. Duration of untreated psychosis and neurocognition in first-episode psychosis: a meta-analysis. Schizophr Res 2018;193:3-10. 23. Watson P, Zhang JP, Rizvi A et al. A meta-analysis of factors associated with quality of life in first episode psychosis. Schizophr Res 2018;202:26-36. 24. Fusar-Poli P, Radua J. Ten simple rules for conducting umbrella reviews. Evid Based Ment Health 2018;21:95-100. 25. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000;283:2008-12. 26. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6: e1000097. 27. Harbord R. Investigating heterogeneity: subgroup analysis and meta-regression. Cochrane Statistical Methods Group Training Course, Cardiff, March 2010. 28. Petkova E, Tarpey T, Huang L et al. Interpreting meta-regression: application to recent controversies in antidepressants’ efficacy. Stat Med 2013;32:2875- 92. 29. Fu R, Gartlehner G, Grant M et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol 2011;64:1187-97. 30. Morrison A, Polisena J, Husereau D et al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care 2012;28:138-44. 31. Higgins JPT, Green S (eds). Cochrane handbook for systematic reviews of interventions. Chichester: Wiley-Blackwell, 2008. 32. Hildebrand J, Thakar S, Watts T-L et al. The impact of environmental cadmium exposure on type 2 diabetes risk: a protocol for an overview of systematic reviews. Syst Rev 2019;8:309. 33. Rohatgi A. WebPlotDigitizer. Version 4.3. Pacifica, 2017. 34. Large M, Nielssen O, Slade T et al. Measurement and reporting of the duration of untreated psychosis. Early Interv Psychiatry 2008;2:201-11. 35. Pearson K.I. Mathematical contributions to the theory of evolution. VII. On the correlation of characters not quantitatively measurable. Philos Trans R Soc Lond Series A 1900;195:1-47. 36. Dunlap WP, Burke MJ. The effect of skew on the magnitude of product-moment correlations. J Gen Psychol 1995;122:365-77. 37. Bishara AJ, Hittner JB. Confidence intervals for correlations when data are not normal. Behav Res Methods 2017;49:294-309. 38. Bonett DG. An introduction to meta-analysis. University of California, Santa Cruz, 2017. 39. Gilpin AR. Table for conversion of Kendall’s tau to Spearman’s rho within the context of measures of magnitude of effect for meta-analysis. Educ Psychol Meas 1993;53:87-92. 40. Rupinski MT, Dunlap WP. Approximating Pearson product-moment correlations from Kendall’s tau and Spearman’s rho. Educ Psychol Meas 1996; 56:419-29. 41. Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ 2006;332:1080. 42. Tirupati NS, Rangaswamy T, Raman P. Duration of untreated psychosis and treatment outcome in schizophrenia patients untreated for many years. Aust N Z J Psychiatry 2004;38:339-43. 43. McGorry PD, Edwards J, Mihalopoulos C et al. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull 1996;22:305-26. 44. Jacobs P, Viechtbauer W. Estimation of the biserial correlation and its sampling variance for use in meta-analysis. Res Synth Methods 2017;8:161- 80. 45. Borenstein M, Hedges LV, Higgins JPT et al (eds). Introduction to meta-anal- ysis. Chichester: Wiley, 2009. 46. Bonett DG. Transforming odds ratios into correlations for meta-analytic research. Am Psychol 2007;62:254-5. 47. Cheng Y, Liu H. A short note on the maximal point-biserial correlation under non-normality. Br J Math Stat Psychol 2016;69:344-51. 48. Souverein OW, Dullemeijer C, van’t Veer P et al. Transformations of summary statistics as input in meta-analysis for linear dose-response models on a logarithmic scale: a methodology developed within EURRECA. BMC Med Res Methodol 2012;12:57. 49. Drake RJ, Husain N, Marshall M et al. Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: a longitudinal analysis and modelling study. Lancet Psychiatry 2020;7:602-10. 50. Ristic-Medic D, Dullemeijer C, Tepsic J et al. Systematic review using metaanalyses to estimate dose-response relationships between iodine intake and biomarkers of iodine status in different population groups. Nutr Rev 2014;72:143-61. 51. Moran VH, Stammers AL, Medina MW et al. The relationship between zinc intake and serum/plasma zinc concentration in children: a systematic review and dose-response meta-analysis. Nutrients 2012;4:841-58. 52. Tenny S, Hoffman MR. Odds ratio (OR). StatPearls Publishing, 2020. 53. Shor E, Roelfs D, Vang ZM. The “Hispanic mortality paradox” revisited: meta-analysis and meta-regression of life-course differentials in Latin American and Caribbean immigrants’ mortality. Soc Sci Med 2017;186:20-33. 54. Viechtbauer W. Conducting meta-analyses in R with the metafor Package. J Stat Softw 2010;36. 55. Egger M, Smith GD, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629. 56. Radua J, Ramella-Cravaro V, Ioannidis JPA et al. What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry 2018;17:49- 66. 57. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-63. 58. Ioannidis JP, Trikalinos TA. An exploratory test for an excess of significant findings. Clin Trials 2007;4:245-53. 59. Kossmeier M, Tran US, Voracek M. metaviz. Version 0.3.1. https://cran.r- project.org/. 60. Rosenberg MS. The file-drawer problem revisited: a general weighted method for calculating fail-safe numbers in meta-analysis. Evolution 2005;59: 464-8. 61. Harrer M, Cuijpers P, Furukawa TA et al. Doing meta-analysis in R: a hands- on guide. PROTECT Lab Erlangen, 2019. 62. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300. 63. Kahn RS, Winter van Rossum I, Leucht S et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry 2018;5:797-807. 64. Oliver D, Davies C, Crossland G et al. Can we reduce the duration of untreated psychosis? A systematic review and meta-analysis of controlled interventional studies. Schizophr Bull 2018;44:1362-72. 65. Farooq S, Large M, Nielssen O et al. The relationship between the duration of untreated psychosis and outcome in low-and-middle income countries: a systematic review and meta analysis. Schizophr Res 2009;109:15-23. 66. Large MM, Nielssen O. Violence in first-episode psychosis: a systematic review and meta-analysis. Schizophr Res 2011;125:209-20. 67. Alvarez-Jimenez M, Priede A, Hetrick SE et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res 2012;139:116-28. 68. Burns JK. Cannabis use and duration of untreated psychosis: a systematic review and meta-analysis. Curr Pharm Des 2012;18:5093-04. 69. Challis S, Nielssen O, Harris A et al. Systematic meta-analysis of the risk factors for deliberate self-harm before and after treatment for first-episode psychosis. Acta Psychiatr Scand 2013;127:442-54. 70. Andreasen NC, Carpenter WT Jr, Kane JM et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441- 9. 71. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophr Bull 2009;35:549-62. 72. Brugger SP, Angelescu I, Abi-Dargham A et al. Heterogeneity of striatal dopamine function in schizophrenia: meta-analysis of variance. Biol Psychiatry 2020;87:215-24. 73. McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry 2020;19:15- 33. 74. Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental- cognitive model. Lancet 2014;383:1677-87. 75. Potkin SG, Kane JM, Correll CU et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr 2020;6:1. 76. Onwordi EC, Halff EF, Whitehurst T et al. Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nat Commun 2020;11:246. 77. Osimo EF, Beck K, Reis Marques T et al. Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures. Mol Psychiatry 2019;24:549-61. 78. Tandberg M, Ueland T, Sundet K et al. Neurocognition and occupational functioning in patients with first-episode psychosis: a 2-year follow-up study. Psychiatry Res 2011;188:334-42. 79. Kaar SJ, Natesan S, McCutcheon R et al. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology 2020;172:107704. 80. Howes OD, McCutcheon R, Agid O et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry 2017;174:216-29. 81. Jonas KG, Fochtmann LJ, Perlman G et al. Lead-time bias confounds association between duration of untreated psychosis and illness course in schizophrenia. Am J Psychiatry 2020;177:327-34.